EQ News and Press, Equillium Inc. From 11/08/23

2023-11-08 17:32:06 ET More on Equillium Seeking Alpha’s Quant Rating on Equillium Historical earnings data for Equillium Financial information for Equillium For further details see: Equillium GAAP EPS of -$0.11 beats by $0.05, revenue of $8.87M be...

$46.3 million in cash at the end of Q3 2023 expected to provide operating runway into 2025 $1.9 million of cash used in operating activities in Q3 2023 Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to d...

Itolizumab continues to show clinically meaningful response in highly proteinuric subjects At Week 28, 73% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR) Itolizumab demonstrated a favorable safety and tolerability profile Equillium , ...

EQUALISE Phase 1b Study in lupus nephritis fully enrolled – topline data in early 2024 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that abs...

Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced a presentation at the 18th Annual Peptide Therapeutics Symposium highlighting EQ302, a second generation orally del...

2023-10-13 15:00:54 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will host a virtual analyst and investor day on Monday, October 16, 2023 at 9 a.m. PT / 12:00 p.m. ET. D...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the JonesTrading 2023 Healthcare Summit taking place October 9 - 11 at the Eden Roc hotel in...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Cantor Fitzgerald Global Healthcare Conference and the LD Micro Main Event Conference. ...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will host investor meetings at the Wells Fargo Healthcare Conference...